EU Supply Integrity Guidelines

Check out Alira Health’s latest publication, “EU Supply Integrity Guidelines”.

In the document, best practices for European distribution and supply integrity management are highlighted as emerged from discussions with Alira Health’s internal experts and industry practitioners. The documents set out the key components of a successful distribution strategy at the corporate and country level and in the pre-launch phase that pharmaceutical companies should adopt for patent-protected medicines in order to increase the effectiveness and performance of European distribution.

Publications
Published on:
June 9, 2021
Written by:
Filippo Benetti, Nerea Blanque

Download Alira Health's EU Supply Integrity Guidelines

Report Download

 

Related news

Due Diligence Research & Development
Publications August 18, 2021
Infographic: Indication Prioritization and Pre-Commercial Value Assessment
Download our infographic on Indication Prioritization and Pre-Commercial Value Assessment.
Research & Development
Events August 8, 2021
Event: BioProcess International
Join Alira Health at BioProcess International on September 20-23, 2021.
Pharma Research & Development
Publications August 2, 2021
Infographic: Prioritization Strategy of R&D Targets for Biotech Company
Download our infographic on Prioritization Strategy of R&D Targets for Biotech Company
Research & Development
Publications May 27, 2021
Buffers – Navigating New Demands On Downstream Raw Materials
The COVID-19 pandemic has put unusual pressures on the supply and demand of raw materials required for the production and purification of biologics. A specific concern for the biomanufacturing(...)
Research & Development
Publications April 26, 2021
Recombinant Human Polyclonal Antibodies to Treat Disease
Congratulations to Alira Health’s Steven Chamow, PhD, Senior Vice President, CMC and founder of Chamow & Associates, and to Bryan Monroe and Chuck Olson, Senior Consultants, on their(...)
Research & Development
News March 15, 2021
Alira Health Welcomes Nikole Siegmund, Vice President, Preclinical
BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is pleased to announce that Nikole Siegmund has joined the firm(...)
Research & Development
Publications March 9, 2021
A Primer on Potency Assays for Release of Biologics
A key criterion in determining the quality of a biologic product is whether it has maintained its biological activity or “potency.”

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.